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Abstract
Objective: Our goal was to assess 
the association between the use of 
nasal continuous positive airway 
pressure (NCPAP) vs. conventional 
ventilation (CV) in premature infants 
and its effects on: 1) growth in the 
NICU and at follow up visits 
2) neurodevelopmental outcomes 
measured by Bayley Infant 
Neurodevelopmental Screener (BINS) 
3) the incidence of retinopathy of 
prematurity (ROP) and chronic lung 
disease (CLD).
Methods: A retrospective chart 
review of two groups of NICU patients 
was conducted. The fi rst group was 
from 1/1999 – 12/2000 (n=140) and 
was managed by CV. The second 
group (n=168) was from 1/2003 – 
12/2004 and was managed primarily 
by NCPAP. Categorical variables were 
analyzed using Pearson Chi Square. 
Mean numerical values were analyzed 
with the student t-test.
Results: There was no statistical 
difference between the groups in 
regard to 15 demographic and 
interventional variables. There were 
signifi cant differences between the two 
groups in CLD (p<0.05) and ROP 
(p<0.01), mean weight at one month 
(p<0.05), 9-12 months (p<0.01) and 
15-18 months (p<0.01), length at 4-6 
months (p<0.05), 9-12 months (p<0.05), 
15-18 months (p<0.01), and 2 years 
(p=.05), and in BINS scores at 9-12 
months (p<0.01) and 15-18 months 
(p<0.01). 
Conclusions: Managing babies 
with NCPAP therapy when compared 
with CV, signifi cantly increased the 
weight at one month which was 
sustained at the 9-12 month and 15-18 
month visits, increased length at all 
follow up visits, increased BINS scores 
at the 9-12 month and 15-18 month 
visits, and decreased the incidence of 
ROP and CLD.
Introduction
Studies over the past twenty 
years have shown an improvement 
in neonatal mortality but 
unfortunately have not shown 
the same for morbidity. Fanaroff 
et. al prospectively studied the 
mortality and morbidity of infants 
501-1500 grams from 1990 to 2002 
at twelve centers of the National 
Institute of Child Health and Human 
Development Neonatal Research 
Network. While it was found that 
mortality decreased in subsequent 
cohorts, survival with one or more 
morbidities increased slightly. In the 
EPIcure Study in the UK (2000), of 
infants 23-26 weeks, fewer than half 
were neurologically intact. Similar 
neurodevelopmental outcomes have 
been reported in the US in studies 
by Hack and Fanaroff (2000) and 
Vohr, Wright, and Dusick (2000). 
While these studies have considered 
effects of such treatment modalities 
as antenatal and postnatal steroids 
and antibiotics, to our knowledge no 
one has studied the effect of NCPAP 
on neurodevelopmental outcomes.
Use of NCPAP in premature 
infants has gained favor. Children’s 
Hospital of New York – Columbia 
University has become known for the 
use of NCPAP which has resulted in 
signifi cantly lower rates of chronic 
lung disease. The association of 
decreased chronic lung disease with 
NCPAP was reported by Avery et. al, 
and has been confi rmed in a survey 
of 11 other American centers. While 
NCPAP is now being used more 
routinely, there still remain questions 
and the body of knowledge 
regarding its use is still growing. 
One issue is it is very resource-
intensive, requiring skilled and 
experienced staff to ensure success 
of the treatment. Additional research 
regarding benefi ts of NCPAP will 
increase universal acceptance and 
make centers less likely to stop 
NCPAP and begin conventional 
ventilation with onset of apnea, 
skin irritation or nurse frustration 
with correct NCPAP positioning. 
Some studies have also shown an 
increased risk of pneumothorax 
and necrotizing enterocolitis.8 
Most importantly regarding the 
need for our research is the fact 
that recent studies acknowledge 
long term consequences including 
neurodevelopmental outcomes 
of CPAP remain undetermined 
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and need to be monitored. 
Research regarding improved 
growth with the use of NCPAP is 
very limited. Geary et. al. found 
the introduction of surfactant at 
delivery followed by immediate 
extubation to CPAP, decreased 
oxygen exposure, and that giving 
early parenteral amino acids in 
extremely low birth weight infants 
was associated with improvements 
in growth and morbidity. Our NICU 
transitioned to NCPAP for the 
primary respiratory support system 
of premature newborns in January 
2002. Within the first year, our 
observations suggested that our 
incidence of chronic lung disease 
had significantly declined. Over 
the next five years it was noted 
anecdotally that our babies seemed 
to achieve catch up in their growth 
and development faster than they 
had when managed by CV. We 
hypothesized that a retrospective 
review would show improved growth 
and improved BINS scores in our 
babies managed with NCPAP. At the 
same time we also opted to look at 
the incidence of ROP and CLD in 
our NICU during these two different 
treatment modes, expecting that 
they would decrease with NCPAP. 
Patients and Methods
A retrospective chart review of 
two groups of NICU patients < 1500 
grams was conducted. The first 
group was from January 1999 – 
December 2000 (n=140) and was 
managed by CV. The second group 
was from January 2003-December 
2004 (n=168) and was managed 
primarily by NCPAP. As in other 
studies of NCPAP10,13 each baby is 
managed individually and if clinical 
condition warrants, implementation 
of CV is executed. Our data showed 
our CV group had a mean of 17.4 
days on the ventilator and no 
NCPAP days. The NCPAP group 
had a mean of 4.5 days on the 
ventilator and 19.2 days on NCPAP. 
So our NCPAP babies were exposed 
to a mean of 12.9 fewer ventilator 
days. Excluded from the study were 
babies who died or had Grade III or 
IV intraventricular hemorrhage. In 
order to evaluate the similarity of the 
two groups, demographic variables 
of gender, gestational age, birth 
weight, birth head circumference, 
birth length, APGAR scores, size 
for gestational age, maternal 
chorioamnionitis, nosocomial 
infections, antenatal steroid use, 
and transport status were compared 
between the two groups. Intervention 
variables compared included the 
use of high calorie formula and 
provision of early intervention 
services. Outcome variables 
measured included mean weight at 
two weeks, one month, 4-6 months, 
9-12 months, 15-18 months, and two 
years. Mean head circumference 
and length were also evaluated at 
these intervals excluding two weeks 
and one month. Also evaluated 
were the percent having CLD 
and ROP. CLD was defined as an 
oxygen requirement at 36 weeks 
post menstrual age. Finally mean 
Bayley Infant Neurodevelopmental 
Screening (BINS) percentage scores 
at 4-6 months, 9-12 months, 15-
18 months, and two years were 
calculated. Because there are a 
different number of BINS criteria at 
the various ages, a percentage of 
criteria met was used rather than 
a raw score. Categorical values 
were analyzed using Pearson Chi 
Square. Mean numerical values 
were analyzed with the student 
t-test. These parametric tests were 
selected because they have higher 
statistical power than non parametric 
tests and we assumed that our NICU 
population has a normal distribution.
Results
There was no statistically 
significant difference between the 
two groups in regard to any of the 
fifteen demographic and intervention 
variables. These variables, which 
were compared to assure similarity 
of the two groups, included gender, 
gestational age, birth weight, birth 
head circumference, birth length, 
Apgar scores, number of small for 
gestational age babies, maternal 
chorioamnionitis, nosocomial 
infections, antenatal steroid use, 
percentage of babies transported 
in, use of high calorie formula, 
and early intervention therapies. It 
should be noted that the % SGA 
was 27.5% in the CV group and 
only 21.4% in the CPAP group. 
While this did not achieve statistical 
significance, it may have had an 
impact on the outcomes studied. The 
Table 1.  Group Demographic and Intervention Variables.
Variable CV CPAP p Value
Male (%) 49 52 0.51
Gestational Age (mean) 29.5 29.3 0.40
Birth Weight (mean) 1140 1148 0.79
Birth Head Circ (mean) 26.5 26.5 0.88
Birth Length (mean) 37.2 37.6 0.34
1 min Apgar (mean) 6.2 6.3 0.82
5 min Apgar (mean) 7.7 7.8 0.76
10 min Apgar (mean) 7.2 7.2 0.99
SGA (%) 27.5 21.4 0.21
Chorioamnionitis (%) 10 7.7 0.49
Nosocomial Infection (%) 31 28 0.51
Antenatal Steroids (%) 57.1 64 0.24
Transports (%) 15 17 0.59
22 Calorie Formula (%) 43 51 0.83
Early Intervention (%) 62 64 0.92
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data and p values related to these 
variables are depicted in Table I. 
Additional assurance of 
similarity between the two groups 
is derived from the fact that the 
same neonatologists were present 
during both time frames. No 
changes were made in feeding 
protocols, antibiotic usage, or 
parental interaction policies 
between the two time periods.
The NCPAP group demonstrated 
significantly improved growth and 
development. The mean one month 
weight in the NCPAP group was 
1449 grams as compared to 1340 
grams in the CV group (p<0.05). 
At the 9-12 month NICU follow up 
clinic visit mean weight was 9.0 kg 
in the NCPAP group and 8.3 kg in 
the CV group (p<0.01). Finally at 
the 15-18 month visit mean weight 
in the NCPAP group was 10.6 
kg as compared to 9.6 kg in the 
CV group (p<0.01). While weight 
was also greater in the NCPAP 
group at 2 weeks, 4-6 months, 
and 2 years, these values were 
not statistically significant. Linear 
growth was significantly greater 
at all measured intervals. At 4-6 
months, the NCPAP mean length 
was 64.4 centimeters as compared 
to 58.2 centimeters in the CV group 
(p<0.05). Similar differences were 
noted at 9-12 months (NCPAP 
= 73 centimeters, CV = 71.5 
centimeters, p<0.05), 15-18 months 
(NCPAP = 81.3 centimeters, CV = 
78.2 centimeters (p<0.01), and 2 
years (NCPAP = 88.5 centimeters, 
CV = 85 centimeters, p=.05). 
Head circumference was also 
monitored and no difference was 
found between the two groups.
The percentage of items 
successfully achieved on the BINS 
was greater in the NCPAP group 
at all follow up visits and was 
statistically significant at the 9-12 
month visit (NCPAP = .91, CV = .77, 
p<0.01) and the 15-18 month visit 
(NCPAP = .84, CV = .69, p<0.01). 
It should be noted that the number 
of babies in the study decreased 
at each subsequent visit. This 
occurred as some were lost to follow 
up and others were discharged 
from the clinic after achieving catch 
up in growth and development. 
See Table 2-4 for full data sets 
regarding growth and BINS scores. 
Incidence of CLD was 18.5% in the 
NCPAP group and 30% in the CV 
group (p<0.05). Incidence of ROP 
was 6% in the NCPAP group and 
15% in the CV group (p<0.01). 
Discussion
As advancements in the field of 
neonatology continue to lead to 
decreased mortality, it is imperative 
that the study of neurodevelopmental 
effects of various treatment 
modalities be ongoing. Just as 
practice changed regarding the 
use of postnatal steroids which 
have been linked to worsened 
neurodevelopmental outcomes, 
we must continue to strive toward 
better interventions, with improved 
outcomes. It has already been 
established that NCPAP decreases 
the incidence of CLD and this was 
confirmed in our NICU as well. As 
was reported in the Geary study7 
as well as ours, it appears NCPAP 
has additional benefits of improved 
growth. Perhaps these babies do not 
have to utilize as many calories for 
repair of lung damage related to CLD 
and for increased work of breathing, 
thereby enabling better growth.
What are possible explanations for 
the improvements in BINS scores? 
It could be directly related to their 
improved growth. Hack (1982) 
found that preterm infants who 
maintain good growth velocity and 
demonstrate catch up growth also 
do better neurodevelopmentally. 
Nutrition has been found to impact 
long term growth and development 
(Adamkin, 2008). Or perhaps it may 
be related to NCPAPs effect on CLD. 
Infants with CLD have poorer growth 
and disruption of normal brain 
Tables II-IV. Comparisons of Weight, Length, and Bailey Infant 
Neurodevelopmental Screener scores.
Table 2. Weight
Age CV CPAP p Value
2 wks (gm) 1170 1194 0.45
1 month (gm) 1340 1449 0.02
4 months (kg) 6.1    (n=87) 6.4    (n=92) 0.15
9 months (kg)  8.3    (n=66) 9.0    (n=59) 0.0009
15 months (kg)  9.6    (n=37) 10.6    (n=48) 0.002
2 years (kg) 11.2    (n=24) 12.1    (n=12) 0.16
Table 3. Length
Age CV CPAP p Value
4 months (cm) 58.2    (n=87) 64.4    (n=92) 0.02
9 months (cm) 71.5    (n=66) 73      (n=59) 0.0009
15 months (cm) 78.2    (n=36) 81.3     (n=48) 0.002
2 years (cm) 85      (n=24) 88.5     (n=12) 0.05
Table IV. BINS 
Age CV CPAP p Value
4 months 0.87    (n=85) 0.89    (n=92) 0.29
9 months 0.77     (n=66) 0.91     (n=59) 0.000
15 months 0.69     (n=37) 0.84     (n=48) 0.006
2 years 0.66     (n=22) 0.74     (n=11) 0.42
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development (Chiriboga, 2003). 
CLD has been found to increase 
the risk for later neurobehavioral 
impairment (Short, 2003). In infants 
less than 1500 gms 15% of those 
with CLD had CP compared with 
only 3-4% of those without CLD 
having CP (Skidmore, Rivers, and 
Hack, 1990). Anecdotally, our nurses 
report parents feel more comfortable 
holding and interacting with babies 
on NCPAP than those who are 
intubated. Therefore NCPAP 
babies may receive more positive 
stimulation because caregivers do 
not fear an accidental extubation.
A weakness of our study was 
the decreasing numbers we had at 
each follow up clinic visit. By the 2 
year visit we only had 24 patients in 
the CV group and 12 in the NCPAP 
group. This of course lowered the 
power of our statistical analysis 
and contributed to the fact that the 
increased weight and increased 
BINS scores at this visit did not have 
statistical significance. However, 
a positive twist may be that part of 
the reason these numbers lowered 
is that we discharge babies prior 
to 2 years if they have achieved 
catch up. Even though we started 
out with more in the NCPAP group 
(168) than in the CV group (140), 
by the two year visit there were 
twice as many in the CV group. 
Some of the decreased numbers 
are the result of babies being lost 
to follow up but the majority is due 
to babies having achieved catch up 
in growth and development. Thus 
more babies in the NCPAP group 
no longer needed our services. 
Weight was not consistently 
significantly higher at every interval. 
Perhaps at two weeks, enough 
time had not elapsed to yet show 
significance. Lack of significance 
at the 4-6 month visit is harder to 
explain as to why we would see 
significance before this at 1 month 
and afterward at 9-12 and 15-18 
months. However linear growth 
difference was significant at every 
measurement (even with the small 
numbers at the 2 year visit) and this 
is generally considered to be a better 
indicator of appropriate nutrition. 
The elevation in the NCPAP BINS 
scores at the 4-6 month visit 
was not significant. This seems 
intuitive as not much is required 
developmentally at this age. As with 
all retrospective studies, association 
is not proof of causality. In order to 
truly compare the effects of NCPAP 
vs. CV on growth and development, 
a randomized, prospective 
study would be necessary.
A strength of our study is the strong 
similarity of the two groups. This is 
evident statistically, having found no 
difference in any of the demographic 
or intervention variables. Similarity 
of treatment protocols was also 
improved by the fact that the same 
neonatologists were practicing 
during both time periods. No 
changes were made in feeding 
protocols during the management of 
either cohort.
Conclusion
The use of NCPAP in premature 
infants has definitely been shown 
to decrease CLD. If it in fact also 
improves growth and development 
this could contribute to reduced 
morbidity in this vulnerable group. 
In our study NCPAP therapy 
in premature babies when 
compared with CV significantly:
Increased weight at one month • 
which was sustained at the 9-12 
month and 15-18 month visits.
Increased BINS scores • 
at the 9-12 month and 
15-18 month visits.
Improved linear growth • 
at all follow up visits.
Decreased the occurrence • 
of CLD and ROP.
We also noted that a greater 
percentage of the NCPAP babies 
were discharged earlier from 
the NICU follow up clinic due to 
complete catch up. Further study is 
needed to investigate the benefits 
of NCPAP use for smaller, sicker 
babies and those with high risk for 
neurodevelopmental abnormalities.
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